|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The latest report Integrin Alpha 4-Pipeline Review H2 2017 outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)-Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. The molecules developed by companies in Phase III Phase II Preclinical and Discovery stages are 2 4 3 and 3 respectively. Report covers products from therapy areas Gastrointestinal Immunology Infectious Disease Oncology Central Nervous System Respiratory Cardiovascular Genetic Disorders Ophthalmology and Toxicology which include indications Ulcerative Colitis Asthma Graft Versus Host Disease (GVHD) Human Immunodeficiency Virus (HIV) Infections (AIDS) Inflammatory Bowel Disease Acute Ischemic Stroke Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Autoimmune Disorders Celiac Disease Chemotherapy Effects Crohn's Disease (Regional Enteritis) Duchenne Muscular Dystrophy Genital Warts (Condylomata Acuminata) Melanoma Multiple Sclerosis Paraneoplastic Syndrome Relapsing Remitting Multiple Sclerosis (RRMS) and Wet (Neovascular / Exudative) Macular Degeneration.
Furthermore this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/integrin-alpha-4-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
- The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881477/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Company Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Company Ltd
Viriom Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881477/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indication H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Pipeline by Antisense Therapeutics Ltd H2 2017
Pipeline by Biogen Inc H2 2017
Pipeline by BioMAS Ltd H2 2017
Pipeline by Daiichi Sankyo Company Ltd H2 2017
Pipeline by EA Pharma Co Ltd H2 2017
Pipeline by Immunwork Inc H2 2017
Pipeline by Morphic Therapeutic Inc H2 2017
Pipeline by Protagonist Therapeutics Inc H2 2017
Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
Pipeline by Viriom Inc H2 2017
Dormant Products H2 2017
Dormant Products H2 2017 (Contd..1) H2 2017
Dormant Products H2 2017 (Contd..2) H2 2017
Discontinued Products H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881477/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
